Hormone Therapy for Perimenopause: What you need to know

Hormone therapy (HT, also called HRT) is the most effective FDA-approved treatment for the hallmark symptoms of perimenopause: hot flashes, night sweats, and vaginal dryness. It is also approved to help prevent bone loss. Some women notice better sleep or mood, often because night sweats ease, though HRT is not approved to treat sleep problems, mood changes, or brain fog. Yet it remains one of the most misunderstood treatments in women’s health.

Much of the fear surrounding HRT traces back to a single study, the Women’s Health Initiative (WHI) in 2002, whose initial results were widely misinterpreted and led to a generation of women being denied effective treatment. Many of these persistent myths about hormone therapy continue to influence both patients and providers today. Since then, decades of follow-up research have fundamentally changed our understanding of both the benefits and risks. This article presents that updated evidence clearly.

What Hormone Therapy Actually Is

During perimenopause, your ovaries produce increasingly erratic and declining levels of estrogen and progesterone. Hormone therapy replaces what your body is producing less of. That’s it. The concept is straightforward, even if the details require thoughtful discussion with your clinician.

There are two main components:

• Estrogen: the primary hormone that addresses hot flashes, night sweats, vaginal dryness, bone loss, and many other symptoms. The preferred form is estradiol (17-beta estradiol), which is molecularly identical to what your ovaries produce and comes in FDA-approved forms. Identical in structure does not mean risk-free.
• Progesterone: required for any woman who still has a uterus, to protect the uterine lining from thickening (which unopposed estrogen can cause). The preferred form is micronized progesterone (brand name Prometrium), an FDA-approved form that is chemically identical to the progesterone your body makes. It can cause drowsiness, so it is usually taken at bedtime.

Types and Delivery Methods

Estrogen Delivery

• Transdermal patch: Applied to the skin, changed once or twice weekly. Bypasses first-pass liver metabolism, which is associated with a lower risk of blood clots than oral estrogen, according to NAMS. Often preferred for patients at higher cardiovascular risk.
• Topical gel or spray: Applied daily to the skin. Same liver-bypass benefit as patches. Good option for women who find patches irritating.
• Oral tablets: Taken daily. Convenient but passes through the liver, which slightly increases clotting risk. Many women use it, though transdermal forms are often preferred when possible.
• Vaginal estrogen: Creams, rings, or inserts that deliver very low-dose estrogen locally. Specifically treats vaginal dryness, painful intercourse, and urinary symptoms. Very little is absorbed into the bloodstream, and guidelines support it for many women who cannot use systemic HRT. It is not risk-free, and anyone with a history of breast cancer should discuss it with their oncology team.

Progesterone Options

• Micronized progesterone (Prometrium): Oral, FDA-approved. Usually taken at bedtime because it can cause drowsiness.
• Hormonal IUD (Mirena): Delivers a progestin (levonorgestrel) directly to the uterus. Some clinicians use it as the progestogen part of HRT while it also provides contraception, which is relevant during perimenopause when pregnancy is still possible.
• Synthetic progestins: Older forms (medroxyprogesterone acetate/Provera) are still used. Some observational data suggest micronized progesterone may carry less breast cancer risk than some synthetic progestins, though the evidence is limited.

What HRT Can Do

The benefits of hormone therapy when started during the window of opportunity are substantial and well-documented. The North American Menopause Society (NAMS) considers HRT the most effective treatment for vasomotor symptoms and recommends it for symptomatic women within the appropriate window:

• Hot flashes and night sweats: NAMS recognizes HRT as the most effective evidence-based treatment for vasomotor symptoms, reducing frequency and severity by 75–90% in clinical trials.
• Vaginal and urogenital health: Significantly improves vaginal atrophy in approximately 75% of women in clinical studies. Also improves urinary symptoms and may reduce recurrent urinary tract infections.
• Bone health: Randomized trial evidence (WHI, 2002) showed a 30–50% reduction in hip fracture risk in women on combined HRT. NAMS recognizes HRT as one of the interventions that can support bone density during the menopausal transition.
• Sleep: Some women sleep better on HRT, often because night sweats ease. HRT is not approved as a sleep treatment, and progesterone’s drowsiness is a side effect, which is why it is taken at bedtime.
• Mood and cognition: Estrogen may improve mood symptoms in perimenopause for some women, especially alongside hot flashes, but HRT is not approved to treat depression, anxiety, or brain fog. For clinical depression, antidepressants and therapy are the first-line treatments.
• Brain health: Studies on HRT and long-term brain health are mixed. HRT is not FDA-approved or recommended for preventing dementia or Alzheimer’s disease, and this remains an active area of research.
• Cardiovascular health: Heart-related risks from HRT appear to rise with age at starting, which is why timing matters. Current guidance does not recommend HRT to prevent heart disease.

The Window of Opportunity

This is perhaps the most important concept in modern HRT science. The window of opportunity (also called the timing hypothesis) means that hormone therapy should ideally be started within 10 years of menopause onset or before age 60.

When started during this window, HRT is associated with:

• Lower heart-related risk than starting later (HRT is not used to prevent heart disease)
• Protection against bone loss
• The most favorable overall balance of benefits and risks

When started well after this window, the risk-benefit calculation shifts, particularly regarding cardiovascular health. As ACOG guidelines on the menopause years note, this does not mean HRT is never appropriate after 60, but the conversation with your clinician should be more nuanced.

The practical implication: if symptoms are affecting your life, there’s no benefit to waiting to learn your options. For women who are good candidates, starting during perimenopause or early postmenopause falls within the window where benefits most often outweigh risks.

Risks: What the Evidence Actually Shows

Any honest discussion of HRT must address risks. Here is what current evidence shows:

• Breast cancer: The most studied concern. Evidence on estrogen-only HRT (for women without a uterus) is mixed: in the WHI trial it did not increase breast cancer risk, while some large observational studies found a small increase with longer use. Combined estrogen + progesterone shows a small increase in risk after 5+ years of use, comparable to the risk increase from drinking one glass of wine daily or being overweight. Using micronized progesterone (instead of synthetic progestins) may carry lower risk, though long-term data is still accumulating.
• Blood clots: Oral estrogen slightly increases clot risk. Observational studies suggest patches and gels carry a lower clot risk than pills, but no form of estrogen is risk-free. This is one reason patches and gels are often preferred.
• Stroke: Very small increased risk with oral estrogen, primarily in women over 60. Transdermal estradiol may carry less risk, though that evidence is observational.
• Uterine (endometrial) cancer: Estrogen taken without a progestogen can thicken the uterine lining and raise endometrial cancer risk. That is why women with a uterus who take systemic estrogen also need a progestogen, such as progesterone.
• Label changes: In late 2025 the FDA began removing the boxed warnings about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy labels, with relabeling rolling out product by product. The boxed warning about endometrial cancer remains for systemic estrogen-alone products, and the labels still list risks and reasons not to use HT.

Who Is HRT For?

Hormone therapy may be a good option if you:

• Have moderate to severe hot flashes or night sweats
• Experience vaginal dryness or painful intercourse
• Are at risk for osteoporosis
• Have night sweats that are disrupting your sleep
• Are under 60 or within 10 years of menopause onset
• Do not have contraindications (breast cancer history, blood clots, etc.)

If you’re unsure, a menopause-trained clinician can help you evaluate your individual risk-benefit profile. This is not a decision you need to make alone, and it is not a decision your doctor should dismiss without a thorough conversation.

Getting Started

If you’re considering HRT, here is what a good initial process looks like:

1. Find a knowledgeable provider. Not all doctors are trained in menopause medicine. Look for NAMS-certified menopause practitioners or clinicians who specialize in perimenopause care.
2. Bring your symptom history. Our free assessment can help you document your symptoms clearly.
3. Discuss delivery methods. Patches and gels may carry a lower clot risk than pills, and women with a uterus also need a progestogen, such as micronized progesterone.
4. Plan for follow-up. Your clinician should check in after 2-3 months to assess response and adjust dosing if needed.
5. Combine with lifestyle changes. HRT works best as part of a comprehensive approach, not as a standalone solution.